Cristina Popa
@nephroseeker.medsky.social
🩺 Nephrologist = kidney philosopher
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC executive editor
📍@KIreportsbsky.social
📍ERAkidney #ERA25 social media co-leader
#NephSky #MedSky
📜History lover
🕊️ Aspiring to be better. Freethinker
📍 #NephJC executive editor
📍@KIreportsbsky.social
📍ERAkidney #ERA25 social media co-leader
#NephSky #MedSky
Reposted by Cristina Popa
Sibeprenlimab: First @fda.gov approved therapy targeting B cells which produce the abnormal antibodies responsible for #IgAN, addressing the fundamental cause
#Nephpearls #NephSky
#VisualAbstract by @nephroseeker.medsky.social
👉🏼 www.fda.gov/drugs/news-e...
👉🏼 pubmed.ncbi.nlm.nih.gov/41211929/
#Nephpearls #NephSky
#VisualAbstract by @nephroseeker.medsky.social
👉🏼 www.fda.gov/drugs/news-e...
👉🏼 pubmed.ncbi.nlm.nih.gov/41211929/
November 27, 2025 at 2:40 AM
Sibeprenlimab: First @fda.gov approved therapy targeting B cells which produce the abnormal antibodies responsible for #IgAN, addressing the fundamental cause
#Nephpearls #NephSky
#VisualAbstract by @nephroseeker.medsky.social
👉🏼 www.fda.gov/drugs/news-e...
👉🏼 pubmed.ncbi.nlm.nih.gov/41211929/
#Nephpearls #NephSky
#VisualAbstract by @nephroseeker.medsky.social
👉🏼 www.fda.gov/drugs/news-e...
👉🏼 pubmed.ncbi.nlm.nih.gov/41211929/
Reposted by Cristina Popa
The lineup of the #TopNephrology stories is live www.nephjc.com/news/2025/11...
If you want to vote, you need to be signed up for the #NephJC Newsletter here www.nephjc.com/newsletter ASAP
If you want to vote, you need to be signed up for the #NephJC Newsletter here www.nephjc.com/newsletter ASAP
Which were the Top Nephrology Stories of 2024? — NephJC
Time to vote for the Top Stories of 2025
www.nephjc.com
November 26, 2025 at 3:55 PM
The lineup of the #TopNephrology stories is live www.nephjc.com/news/2025/11...
If you want to vote, you need to be signed up for the #NephJC Newsletter here www.nephjc.com/newsletter ASAP
If you want to vote, you need to be signed up for the #NephJC Newsletter here www.nephjc.com/newsletter ASAP
Reposted by Cristina Popa
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial - PubMed
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3 …
pubmed.ncbi.nlm.nih.gov
November 26, 2025 at 11:10 PM
Apixaban and warfarin being similar is also a red flag
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
And with LAOO is such a huge selection bias
The SAFE-D trial (pilot; pubmed.ncbi.nlm.nih.gov/39495569/) is now funded to examine apixaban properly
#NephSky
Reposted by Cristina Popa
👇Here are the proposals for the #TopNephrology stories in 2025
🔥 Remember, you can only vote for your favorites if you have subscribed to #NephJC newsletter
📬 Soon we'll send you the voting link. Check your email.
www.nephjc.com/news/2025/11...
🔥 Remember, you can only vote for your favorites if you have subscribed to #NephJC newsletter
📬 Soon we'll send you the voting link. Check your email.
www.nephjc.com/news/2025/11...
Which were the Top Nephrology Stories of 2024? — NephJC
Time to vote for the Top Stories of 2025
www.nephjc.com
November 26, 2025 at 3:45 PM
👇Here are the proposals for the #TopNephrology stories in 2025
🔥 Remember, you can only vote for your favorites if you have subscribed to #NephJC newsletter
📬 Soon we'll send you the voting link. Check your email.
www.nephjc.com/news/2025/11...
🔥 Remember, you can only vote for your favorites if you have subscribed to #NephJC newsletter
📬 Soon we'll send you the voting link. Check your email.
www.nephjc.com/news/2025/11...
It began in 2021, wondering why anyone would pick me for #NSMC. I applied in '22 and was surprised to be accepted. I’ve grown thanks to many of you (@hswapnil.medsky.social @kidneyboy.bsky.social ), though I still feel like a newcomer 😊
🙏 Grateful to be in this with @brianrifkin.bsky.social #NephJC
🙏 Grateful to be in this with @brianrifkin.bsky.social #NephJC
An announcement
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
www.nephjc.com/news/2025/11...
#NephJC
@kidneyboy.bsky.social and moi hand over the @nephjc.bsky.social reigns to @nephroseeker.medsky.social & @brianrifkin.bsky.social
Taking the reigns — NephJC
In April 2014, Swapnil and I launched NephJC—and within weeks we were overwhelmed by the sheer work of running a twice-monthly, Twitter-based journal club. Fortunately, we also had a deep bench of fri...
www.nephjc.com
November 26, 2025 at 3:16 AM
It began in 2021, wondering why anyone would pick me for #NSMC. I applied in '22 and was surprised to be accepted. I’ve grown thanks to many of you (@hswapnil.medsky.social @kidneyboy.bsky.social ), though I still feel like a newcomer 😊
🙏 Grateful to be in this with @brianrifkin.bsky.social #NephJC
🙏 Grateful to be in this with @brianrifkin.bsky.social #NephJC
Probably #nephsky will never see a trial comparing spironolactone with finerenone
Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials
pubmed.ncbi.nlm.nih.gov/41173939/
Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials
pubmed.ncbi.nlm.nih.gov/41173939/
November 25, 2025 at 11:38 AM
Probably #nephsky will never see a trial comparing spironolactone with finerenone
Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials
pubmed.ncbi.nlm.nih.gov/41173939/
Target emulated trial: potential benefits of finerenone in all sorts of outcomes, but we’re comparing 🔝methodology trials (FIGARO, FIDELIO) vs invetigator initiated trials
pubmed.ncbi.nlm.nih.gov/41173939/
Reposted by Cristina Popa
#NephJCshort on BICAR-ICU2 #Medsky #Nephsky
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
Dialysis deferred, logic recycled: BICAR ICU2 — NephJC
NephJC short on BICAR-ICU2
www.nephjc.com
November 25, 2025 at 12:19 AM
#NephJCshort on BICAR-ICU2 #Medsky #Nephsky
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
✍️ By @nephroseeker.medsky.social
🎭 Bicarbonate makes the picture look cleaner: better pH, more time. But beneath the smoother numbers, the patient hasn't changed. It's the same story, just told in softer colors
www.nephjc.com/news/2025/10...
Reposted by Cristina Popa
In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v
November 24, 2025 at 2:13 PM
In older patients with frailty who were receiving antihypertensive drugs and had a systolic blood pressure below 130 mm Hg, reducing antihypertensive drugs did not lead to lower all-cause mortality over 4 years than usual care. Full RETREAT-FRAIL trial results and Research Summary: nej.md/45NUK9v
Reposted by Cristina Popa
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
November 20, 2025 at 6:47 PM
🧵 New #Skeetorial Drop! 🧵
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
1/ Hey #NephSky! 👋
We’re back with a fresh #Skeetorial from @kireports.bsky.social , this time diving into:
Dapagliflozin in Stage 4 CKD: no diabetes required? 🤔
Let’s unpack what this trial means for your next CKD patient. 💊💭
Reposted by Cristina Popa
Every year, #NephJC celebrates successful, practice-changing trials. ✨ Which trials do you think are deserving for #TopNephrology 2025? #nephsky
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
Top Stories in Nephrology 2024 — NephJC
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every b...
www.nephjc.com
November 20, 2025 at 10:42 PM
Every year, #NephJC celebrates successful, practice-changing trials. ✨ Which trials do you think are deserving for #TopNephrology 2025? #nephsky
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
👇👇 Here's a throwback for 2024
www.nephjc.com/news/2024/1/...
Reposted by Cristina Popa
5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
November 20, 2025 at 12:35 AM
5/10
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
A figure paints🖼️ a 1000 words!
Emerging evidence from APRIL/BAFF–axis trials underscores how central this pathway is to IgAN biology. Let’s put ORIGIN side by side with the others and see what we learn!
Reposted by Cristina Popa
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
November 20, 2025 at 12:34 AM
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Reposted by Cristina Popa
Up next: It might seem a little fishy, but was a great catch 🎣 #NephJC
PISCES, the use of fish oil to decrease mortality in dialysis patients.
www.pubmed.ncbi.nlm....
PISCES, the use of fish oil to decrease mortality in dialysis patients.
www.pubmed.ncbi.nlm....
November 19, 2025 at 2:58 AM
Up next: It might seem a little fishy, but was a great catch 🎣 #NephJC
PISCES, the use of fish oil to decrease mortality in dialysis patients.
www.pubmed.ncbi.nlm....
PISCES, the use of fish oil to decrease mortality in dialysis patients.
www.pubmed.ncbi.nlm....
Reposted by Cristina Popa
#MassSpectrometry of Minimal Change Disease and Focal Segmental Glomerulosclerosis #MCD #FSGS
#VisualAbstract by Sophia Ambruso
https://www.kireports.org/article/S2468-0249(25)00618-7/fulltext
#VisualAbstract by Sophia Ambruso
https://www.kireports.org/article/S2468-0249(25)00618-7/fulltext
November 19, 2025 at 12:00 AM
#MassSpectrometry of Minimal Change Disease and Focal Segmental Glomerulosclerosis #MCD #FSGS
#VisualAbstract by Sophia Ambruso
https://www.kireports.org/article/S2468-0249(25)00618-7/fulltext
#VisualAbstract by Sophia Ambruso
https://www.kireports.org/article/S2468-0249(25)00618-7/fulltext
Reposted by Cristina Popa
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
November 19, 2025 at 2:42 AM
T3g: #NephJC
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Although sibeprenlimab targets APRIL alone while atacicept blocks both BAFF and APRIL, the two trials showed broadly similar clinical effects: meaningful reductions in proteinuria, strong improvements in key biomarkers, and high rates of hematuria resolution.
Reposted by Cristina Popa
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
November 19, 2025 at 2:41 AM
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Reposted by Cristina Popa
#NephJC
Here we are, staring into nephro-void, where yesterday’s paradigm dissolves. IgAN therapy was a Sisyphian task- rolling the stone of CKD progression uphill, knowing it will tumble back down. A new era brings new hopes. Is ORIGIN 3 another IgAN success story?
pubmed.ncbi.nlm.nih....
Here we are, staring into nephro-void, where yesterday’s paradigm dissolves. IgAN therapy was a Sisyphian task- rolling the stone of CKD progression uphill, knowing it will tumble back down. A new era brings new hopes. Is ORIGIN 3 another IgAN success story?
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:00 AM
#NephJC
Here we are, staring into nephro-void, where yesterday’s paradigm dissolves. IgAN therapy was a Sisyphian task- rolling the stone of CKD progression uphill, knowing it will tumble back down. A new era brings new hopes. Is ORIGIN 3 another IgAN success story?
pubmed.ncbi.nlm.nih....
Here we are, staring into nephro-void, where yesterday’s paradigm dissolves. IgAN therapy was a Sisyphian task- rolling the stone of CKD progression uphill, knowing it will tumble back down. A new era brings new hopes. Is ORIGIN 3 another IgAN success story?
pubmed.ncbi.nlm.nih....
Reposted by Cristina Popa
T0e: #NephJC
The 4 hit model 🔨of IgAN pathophysiology gave us coherence where there was once only chaos: abnormal Gd‑IgA1 production, recognition by antiglycan antibodies, immune complex assembly & mesangial deposition
pubmed.ncbi.nlm.nih....
The 4 hit model 🔨of IgAN pathophysiology gave us coherence where there was once only chaos: abnormal Gd‑IgA1 production, recognition by antiglycan antibodies, immune complex assembly & mesangial deposition
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:12 AM
T0e: #NephJC
The 4 hit model 🔨of IgAN pathophysiology gave us coherence where there was once only chaos: abnormal Gd‑IgA1 production, recognition by antiglycan antibodies, immune complex assembly & mesangial deposition
pubmed.ncbi.nlm.nih....
The 4 hit model 🔨of IgAN pathophysiology gave us coherence where there was once only chaos: abnormal Gd‑IgA1 production, recognition by antiglycan antibodies, immune complex assembly & mesangial deposition
pubmed.ncbi.nlm.nih....
Reposted by Cristina Popa
T0d: #NephJC
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:11 AM
T0d: #NephJC
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
🛑Remission is defined an eGFR decline of ~1 ml/min/1.73 m²/year, closer to physiological rate
📉Vs 2-3 ml per year with only conservative therapy; hopefully, B-cell therapies will further flatten the slope
By @brendonneuen.bsky.social &Co
pubmed.ncbi.nlm.nih....
Reposted by Cristina Popa
T0b: #NephJC
We already discussed the @kdigo.org IgAN guidelines, with the feeling they will soon be outdated. Our topic tonight was only mentioned as future research direction
www.nephjc.com/news/...
We already discussed the @kdigo.org IgAN guidelines, with the feeling they will soon be outdated. Our topic tonight was only mentioned as future research direction
www.nephjc.com/news/...
November 19, 2025 at 2:09 AM
T0b: #NephJC
We already discussed the @kdigo.org IgAN guidelines, with the feeling they will soon be outdated. Our topic tonight was only mentioned as future research direction
www.nephjc.com/news/...
We already discussed the @kdigo.org IgAN guidelines, with the feeling they will soon be outdated. Our topic tonight was only mentioned as future research direction
www.nephjc.com/news/...
Reposted by Cristina Popa
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
www.nephjc.com
November 18, 2025 at 12:32 PM
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Reposted by Cristina Popa
Whoah
EBV not only causes multiple sclerosis, it also might be the root of SLE
www.science.org/doi/10.1126/...
An EBV vaccine to rid ourselves of these horrible autoimmune conditions (and many cancers)?
#lupus #medsky #RheumSky
@christosargyrop.bsky.social
EBV not only causes multiple sclerosis, it also might be the root of SLE
www.science.org/doi/10.1126/...
An EBV vaccine to rid ourselves of these horrible autoimmune conditions (and many cancers)?
#lupus #medsky #RheumSky
@christosargyrop.bsky.social
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus
Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells to promote pathogenic antinuclear T and B cell responses in lupus.
www.science.org
November 13, 2025 at 11:05 PM
Whoah
EBV not only causes multiple sclerosis, it also might be the root of SLE
www.science.org/doi/10.1126/...
An EBV vaccine to rid ourselves of these horrible autoimmune conditions (and many cancers)?
#lupus #medsky #RheumSky
@christosargyrop.bsky.social
EBV not only causes multiple sclerosis, it also might be the root of SLE
www.science.org/doi/10.1126/...
An EBV vaccine to rid ourselves of these horrible autoimmune conditions (and many cancers)?
#lupus #medsky #RheumSky
@christosargyrop.bsky.social
Reposted by Cristina Popa
16 is same as last year
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
Kidney Week in Houston: Day 1 — NephJC
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
www.nephjc.com
November 9, 2025 at 11:31 PM
16 is same as last year
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
someone check if I have missed anything
Read our blogs here www.nephjc.com/news/kidneyw...
#NephJC #KidneyWk
@nephroseeker.medsky.social @brendonneuen.bsky.social
Reposted by Cristina Popa
November 8, 2025 at 5:21 PM